https://www.cmoapi.com/product/orlistat/ What are the side effects of orlistat

1. What are the side effects of orlistat?
Obesity has reached epidemic levels nationwide. It is associated
with increased risk of many other diseases, including diabetes,
coronary heart disease, and certain cancers.including a
reduced-calorie diet, increased physical activity, and behavior
therapy, should be the cornerstone of any weight-loss program.
Drug therapy should always be used in conjunction with lifestyle
changes. Orlistat provides an FDA-approved OTC option for weight
loss. Patients should be educated about the importance of
continued behavior modification if orlistat is added.
Because the absorption of orlistat is minimal, there are very few
systemic effects. Common adverse effects are gastrointestinal (GI)
and are caused by the increased amount of fat in the GI tract. These
effects may include flatulence with discharge, fecal urgency, oily
spotting, fatty or oily stool, abdominal pain or discomfort, and
increased defecation. These symptoms seem to improve over time,
usually lasting no longer than 4 weeks. Rarely, severe liver injury has
been reported with orlistat use, but a causal relationship has not
been established. Patients should be instructed to stop taking
orlistat and to speak with their healthcare provider if they develop
signs and symptoms of liver injury, including itching, yellowed eyes

2. or skin, dark urine, fever, right-upper-quadrant abdominal pain, or
loss of appetite.
Some common side effects include flatulence, frequent bowel
movements, soft stool, oily rectal leakage, and abdominal pain.
Speak with a healthcare provider if any of these side effects become
severe or troublesome. If you experience any serious side effects,
such as hives, rash, skin blistering, right-sided upper stomach or
abdominal pain, pain radiating toward the back, or fever, stop taking
the medication and immediately contact a healthcare provider.
Reference
1. Peng-Yu, Yang (December 2009). "Activity-Based Proteome Profiling
of Potential CellularTargets of Orlistat -An FDA-Approved Drug with
Anti-TumorActivities". Journal of the American Chemical Society. 132 (2):
656–66. doi:10.1021/ja907716f. PMID 20028024 – via researchgate.net.
2. Yang, Peng-Yu; Wang, Min; Liu, Kai; Ngai, Mun Hong; Sheriff, Omar;
Lear, Martin J.; Sze, Siu Kwan; He, Cynthia Y.; Yao, Shao Q. (2 July 2012).
"Parasite-based screening and proteome profiling reveal orlistat, an
FDA-approved drug, as a potential anti Trypanosoma brucei agent".
Chemistry (Weinheim an der Bergstrasse, Germany). 18 (27): 8403–8413.
doi:10.1002/chem.201200482. ISSN 1521-3765. PMID 22674877.
3. 2006 Physicians' Desk Reference (PDR). Thomson PDR. 2006. ISBN

3. 978-1-56363-527-4.
4. "Chemists to provide obesity pill". BBC News Online. 21 January
2009. Retrieved 22 January 2009.
https://www.cmoapi.com/
https://www.cmoapi.com/product/orlistat/
https://www.facebook.com/Cmoapi-114510347044359/
https://www.pinterest.com/cmoapibiotech/boards/